Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China

Table 3 Analysis (grouped according to dose) of change of BPRS total scores (before and after treatment)

Visit time	Mean	95%CIL	95%CIU	F	P-value
2 weeks or 4 weeks
Low dose group	− 11.4	− 12.1	− 10.7
Medium to high dose group	− 11.3	− 12.1	− 10.4
Higher dose group	− 7.3	− 10.1	− 4.5
Low vs. Medium to high	− 0.1	− 1.2	0.9	− 0.268	0.789
Low vs. Higher	− 4.1	− 7.0	− 1.2	− 2.810	0.005
Medium to high vs. Higher	− 4.0	− 6.9	− 1.0	− 2.663	0.008
6 weeks or 8 weeks
Low dose group	− 16.6	− 17.3	− 15.9
Medium to high dose group	− 17.6	− 18.5	− 16.7
Higher dose group	− 12.6	− 15.6	− 9.6
Low vs. Medium to high	1.0	− 0.2	2.1	1.682	0.093
Low vs. Higher	− 4.0	− 7.0	− 0.9	− 2.521	0.012
Medium to high vs. Higher	− 5.0	− 8.1	− 1.8	− 3.098	0.002
12 weeks
Low dose group	− 20.0	− 20.8	− 19.3
Medium to high dose group	− 21.8	− 22.8	− 20.8
Higher dose group	− 18.2	− 21.4	− 15.0
Low vs. Medium to high	1.8	0.6	3.0	2.876	0.004
Low vs. Higher	− 1.8	− 5.1	1.5	− 1.087	0.277
Medium to high vs. Higher	− 3.6	− 6.9	− 0.3	− 2.130	0.033

ISSN: 1744-859X